Tirzepatide vs 5-Amino-1MQ

A dual GIP and GLP-1 receptor agonist producing the largest sustained weight reductions of any drug currently licensed, averaging 20–22% body weight loss in clinical trials.

A first-in-class NNMT (nicotinamide N-methyltransferase) inhibitor that redirects cellular energy toward metabolic acceleration. Early clinical pipeline; widely used in biohacker fat-loss protocols.

Tirzepatide activates both GIP and GLP-1 receptors, a combination that appears to amplify glucose-dependent insulin secretion, slow gastric emptying, and suppress appetite beyond what either pathway achieves alone.

5-Amino-1MQ inhibits NNMT, reducing methyl-nicotinamide accumulation and increasing cellular NAD+/SAM levels. The downstream effect is improved metabolic throughput and reduced fat storage.

2.5 mg weekly, titrated up to 15 mg weekly

50–150 mg daily oral (research protocols)

~5 days

Short — typically daily dosing

Subcutaneous once weekly

Oral

approved

investigational

Not yet listed

Not yet listed